Personalized therapy for advanced ovarian cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests a personalized cancer therapy designed just for you and your tumor. It is for people with newly diagnosed advanced ovarian cancer who can wait a short time before starting treatment and plan to have surgery after 2 cycles of chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with advanced ovarian, peritoneal, or fallopian tube cancer (stage III or IV) or a related type called carcinosarcoma.
- Your cancer does not need immediate treatment or surgery—you can wait at least 2 weeks after diagnosis.
- You are planning to have surgery after 2 rounds of chemotherapy (called interval debulking).
- You are in reasonably good health (able to do daily activities—ECOG score 0, 1, or 2).
- Your liver and kidney function tests are within acceptable limits.
- You are not pregnant or breastfeeding, and have no other active cancer that would affect your outlook.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial compares two different treatment strategies as the first chemotherapy after surgery for advanced epithelial ovarian, peritoneal, or fallopian-tube cancer. It may help doctors find a more effective or better-tolerated approach for people in your situation.
This trial tests a personalized vaccine made from your tumor's genetic material. It is given after surgery to help your immune system recognize and attack any remaining cancer cells, with the goal of preventing the cancer from coming back.
This trial tests a new combination of drugs given before surgery to shrink advanced ovarian cancer, which may make it easier to remove and improve outcomes. It includes an immunotherapy drug that helps your immune system fight cancer, along with standard chemotherapy.
This trial tests a personalized (adaptive) chemotherapy plan for people with certain types of ovarian/fallopian tube/peritoneal cancer who already had platinum chemotherapy and a PARP inhibitor. It’s for patients whose cancer came back after (or still responds to) prior platinum treatment and may help delay disease progression.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) that are trained to recognize specific markers on your ovarian cancer. The goal is to see if this vaccine is safe and helps your immune system fight the cancer.
Hear when a new Carcinoma, Ovarian Epithelial trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.